NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia to Showcase MammaPrint and BluePrint Utility in Guiding Anthracycline Therapy at the 2025 San Antonio Breast Cancer Symposium
Four additional poster presentations from the ongoing real-world FLEX Study highlight the value of real-world data in personalizing chemotherapy decisions and improving outcomes in early-stage breast cancer IRVINE, Calif., and AMSTERDAM — November 25, Read More
Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – August 12, 2025 – Agendia, Inc., a leader in innovative genomic testing for breast cancer, today announced the publication of new findings in JNCI Cancer Spectrum validating Read More
Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO Annual Meeting
FLEX Study Highlights Clinical Utility of MammaPrint® and BluePrint® in Diverse Patient Populations Across Breast Cancer Subtypes IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – May 27, 2025 – Agendia®, Inc., a leader in precision Read More
Newsroom
News, Stories & Breast Cancer Blog
Breast Cancer Statistics 2024
Authors Angela N. Giaquinto MSPH | Hyuna Sung PhD | Lisa A. Newman MD, MPH | Rachel A. Freedman MD, MPH | Robert A. Smith PhD | Jessica Star MA, MPH | Ahmedin Jemal Read More
Anthracyclines and Treatment of Early-Stage Breast Cancer
For decades, anthracyclines have played an important role in treating early-stage breast cancer. But whether this class of drugs should continue to be recommended in early disease given that other available therapies are less Read More
Improving Tailored Treatment Plans in HR+ and HER2- Early Breast Cancer
Genomic profiling in the FLEX trial predicted chemotherapy response in HR+, HER2- breast cancer, which could enable tailored treatment plans. In an abstract presented at the 2024 San Antonio Breast Cancer Symposium, researchers used genomic profiling in Read More
Healthcare Tech Outlook Named Agendia as One of the Top 10 Precision Oncology Solutions Providers in 2024
We are happy to announce Agendia has been named one of the Top 10 Precision Oncology Solutions Providers in 2024. Agendia is proud to be a part of the precision medicine movement with our Read More
What Is Neoadjuvant Chemotherapy?
If you or a loved one has been diagnosed with cancer, your care team may recommend chemotherapy, one of the most common types of cancer treatment available. Chemotherapy involves the use of medications that Read More
What Can We Learn From A Highly Diverse Observational Study Of 17,000+ Breast Cancer Patients?
A conversation with Agendia CMO William Audeh, MD More than 17,000 patients have enrolled in Agendia’s FLEX trial studying full genome profiling and complete clinical data for those diagnosed with stages I, II, or Read More
How Agendia is personalizing breast cancer treatment
By Abbey Bowling | October 29, 2024 October is Breast Cancer Awareness Month, and Agendia, one of the leading providers in the field of precision oncology is working to make a significant impact in Read More
